Anti-Parkinson medication

Beth Israel Deaconess Medical Center · Phase 2 active Small molecule

Anti-Parkinson medication is a Dopamine agonist Small molecule drug developed by Beth Israel Deaconess Medical Center. It is currently in Phase 2 development for Parkinson's disease, Flu-like syndrome. Also known as: Carbidopa/levodopa, pramipexole, ropinirole, amantadine.

This drug works by increasing dopamine levels in the brain to alleviate Parkinson's symptoms.

This drug works by increasing dopamine levels in the brain to alleviate Parkinson's symptoms. Used for Parkinson's disease, Flu-like syndrome.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

• Baseline phase 2 → approval rate +15.3pp
  Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
• CNS / neurology attrition -3.0pp
  CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Anti-Parkinson medication
Also known as	Carbidopa/levodopa, pramipexole, ropinirole, amantadine, tolcapone
Sponsor	Beth Israel Deaconess Medical Center
Drug class	Dopamine agonist
Target	Dopamine receptor
Modality	Small molecule
Therapeutic area	Neurology
Phase	Phase 2

Mechanism of action

It does this by inhibiting the enzyme responsible for breaking down dopamine, allowing more dopamine to be available for the brain's use. This leads to improved motor function and reduced symptoms of Parkinson's disease.

Approved indications

• Parkinson's disease
• Flu-like syndrome

Common side effects

• Nausea
• Dizziness
• Headache
• Fatigue
• Dyskinesia

Key clinical trials

• Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease
• Role of Pentoxifylline and Celecoxib in Parkinsonism (PHASE2)
• Gait Analysis in Neurological Disease
• Investigating the Neural Signature of Freezing of Gait in Parkinson's Disease
• Neuroprotective Effects of Long-term TaVNS in Early Parkinson's Disease Patients (NA)
• An Open-label Study on the Clinical Efficacy of tDCS Intervention in PD (NA)
• Effects of a Periodic Repetitive Transcranial Magenetic Stimulation in Parkinson Disease (NA)
• Safety and Efficacy of Botulinum Toxin A for Treatment of Overactive Bladder in Parkinson's Disease (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Anti-Parkinson medication CI brief — competitive landscape report
• Anti-Parkinson medication updates RSS · CI watch RSS
• Beth Israel Deaconess Medical Center portfolio CI

Frequently asked questions about Anti-Parkinson medication

What is Anti-Parkinson medication?

Anti-Parkinson medication is a Dopamine agonist drug developed by Beth Israel Deaconess Medical Center, indicated for Parkinson's disease, Flu-like syndrome.

How does Anti-Parkinson medication work?

This drug works by increasing dopamine levels in the brain to alleviate Parkinson's symptoms.

What is Anti-Parkinson medication used for?

Anti-Parkinson medication is indicated for Parkinson's disease, Flu-like syndrome.

Who makes Anti-Parkinson medication?

Anti-Parkinson medication is developed by Beth Israel Deaconess Medical Center (see full Beth Israel Deaconess Medical Center pipeline at /company/beth-israel-deaconess-medical-center).

Is Anti-Parkinson medication also known as anything else?

Anti-Parkinson medication is also known as Carbidopa/levodopa, pramipexole, ropinirole, amantadine, tolcapone.

What drug class is Anti-Parkinson medication in?

Anti-Parkinson medication belongs to the Dopamine agonist class. See all Dopamine agonist drugs at /class/dopamine-agonist.

What development phase is Anti-Parkinson medication in?

Anti-Parkinson medication is in Phase 2.

What are the side effects of Anti-Parkinson medication?

Common side effects of Anti-Parkinson medication include Nausea, Dizziness, Headache, Fatigue, Dyskinesia.

What does Anti-Parkinson medication target?

Anti-Parkinson medication targets Dopamine receptor and is a Dopamine agonist.

Related

• Drug class: All Dopamine agonist drugs
• Target: All drugs targeting Dopamine receptor
• Manufacturer: Beth Israel Deaconess Medical Center — full pipeline
• Therapeutic area: All drugs in Neurology
• Indication: Drugs for Parkinson's disease
• Indication: Drugs for Flu-like syndrome
• Also known as: Carbidopa/levodopa, pramipexole, ropinirole, amantadine, tolcapone